ZA200104026B - New esters derived from substituted phenyl-cyclohexyl compounds. - Google Patents
New esters derived from substituted phenyl-cyclohexyl compounds. Download PDFInfo
- Publication number
- ZA200104026B ZA200104026B ZA200104026A ZA200104026A ZA200104026B ZA 200104026 B ZA200104026 B ZA 200104026B ZA 200104026 A ZA200104026 A ZA 200104026A ZA 200104026 A ZA200104026 A ZA 200104026A ZA 200104026 B ZA200104026 B ZA 200104026B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- dimethylaminomethyl
- alkyl
- compound
- cyclohexyl
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title description 12
- 125000004351 phenylcyclohexyl group Chemical group C1(=CC=CC=C1)C1(CCCCC1)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- -1 2,5- dichlorophenylamino Chemical group 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 17
- 229960004380 tramadol Drugs 0.000 description 16
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 16
- 230000000202 analgesic effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- UWJUQVWARXYRCG-UHFFFAOYSA-N o-desmethyltramadol Chemical compound CN(C)CC1CCCCC1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 206010022998 Irritability Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BDPAJJIAIBKWER-UHFFFAOYSA-N n,n-dimethyl-1-(2-phenylcyclohexyl)methanamine Chemical compound CN(C)CC1CCCCC1C1=CC=CC=C1 BDPAJJIAIBKWER-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 1
- IOZUASLAORDSIM-UHFFFAOYSA-N (2-carbonochloridoylphenyl) n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC=C1C(Cl)=O IOZUASLAORDSIM-UHFFFAOYSA-N 0.000 description 1
- GSURLQOKWRJLPY-UHFFFAOYSA-N 2-(1-methylnaphthalen-2-yl)acetic acid Chemical compound C1=CC=C2C(C)=C(CC(O)=O)C=CC2=C1 GSURLQOKWRJLPY-UHFFFAOYSA-N 0.000 description 1
- RGXFLYSKRVEBMO-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexen-1-yl]phenol Chemical compound C1CCCC(CN(C)C)=C1C1=CC=CC(O)=C1 RGXFLYSKRVEBMO-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HPUAIJLEUZEGSX-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenyl] 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 HPUAIJLEUZEGSX-UHFFFAOYSA-N 0.000 description 1
- RRSATROXEHXOFS-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenyl] 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylate Chemical compound CN(C)CC1CCCCC1(O)C1=CC=CC(OC(=O)C2C=3N(C(=CC=3)C(=O)C=3C=CC=CC=3)CC2)=C1 RRSATROXEHXOFS-UHFFFAOYSA-N 0.000 description 1
- VSYDSHZDEPSIIO-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]cyclohexen-1-yl]phenyl] 2-hydroxybenzoate Chemical compound C1CCCC(CN(C)C)=C1C1=CC=CC(OC(=O)C=2C(=CC=CC=2)O)=C1 VSYDSHZDEPSIIO-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008379 phenol ethers Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- XVLIPSQRKZVECE-UHFFFAOYSA-N phenyl 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OC1=CC=CC=C1 XVLIPSQRKZVECE-UHFFFAOYSA-N 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C219/30—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009802329A ES2141688B1 (es) | 1998-11-06 | 1998-11-06 | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104026B true ZA200104026B (en) | 2002-05-17 |
Family
ID=8305698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104026A ZA200104026B (en) | 1998-11-06 | 2001-05-17 | New esters derived from substituted phenyl-cyclohexyl compounds. |
Country Status (39)
Country | Link |
---|---|
US (1) | US6455585B1 (de) |
EP (3) | EP1219623B1 (de) |
JP (1) | JP2002529442A (de) |
KR (1) | KR100453613B1 (de) |
CN (1) | CN1176902C (de) |
AP (1) | AP1222A (de) |
AT (3) | ATE257817T1 (de) |
AU (1) | AU755681B2 (de) |
BG (1) | BG105556A (de) |
BR (1) | BR9915727A (de) |
CA (1) | CA2349245A1 (de) |
CR (1) | CR6368A (de) |
CU (1) | CU23006A3 (de) |
CZ (1) | CZ20011500A3 (de) |
DE (3) | DE69911235T2 (de) |
DK (3) | DK1219623T3 (de) |
EA (1) | EA003742B1 (de) |
EE (1) | EE200100246A (de) |
ES (4) | ES2141688B1 (de) |
GE (1) | GEP20033116B (de) |
HR (1) | HRP20010412B1 (de) |
HU (1) | HUP0104218A3 (de) |
ID (1) | ID29017A (de) |
IL (1) | IL142592A0 (de) |
IS (1) | IS5934A (de) |
MA (1) | MA26765A1 (de) |
MX (1) | MXPA01004432A (de) |
NO (1) | NO20012234L (de) |
NZ (1) | NZ511739A (de) |
OA (1) | OA11672A (de) |
PL (1) | PL347492A1 (de) |
PT (3) | PT1219623E (de) |
SI (3) | SI1127871T1 (de) |
SK (1) | SK284068B6 (de) |
TR (3) | TR200200416T2 (de) |
UA (1) | UA59477C2 (de) |
WO (1) | WO2000027799A1 (de) |
YU (1) | YU29601A (de) |
ZA (1) | ZA200104026B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2160534B1 (es) * | 1999-12-30 | 2002-04-16 | Vita Invest Sa | Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo. |
DE10049483A1 (de) * | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte 1-Aminobutan-3-ol-Derivate |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
WO2004026291A1 (fr) * | 2002-08-28 | 2004-04-01 | Shuyi Zhang | Formulations orales d'ibuprofene et de tramadol, methodes de preparation de ces dernieres |
ATE391498T1 (de) * | 2002-11-22 | 2008-04-15 | Gruenenthal Gmbh | Verwendung von (1rs,3rs,6rs)-6- dimethylaminomethyl-1-(3-methoxy-phenyl)- cyclohexan-1,3-diol zur behandlung von entzündungsschmerz |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004034619A1 (de) * | 2004-07-16 | 2006-02-23 | Grünenthal GmbH | Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
PL2273983T3 (pl) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego |
JP5667183B2 (ja) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 加熱溶融押出成型した制御放出性投与剤型 |
WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
EP2383255A1 (de) * | 2010-04-28 | 2011-11-02 | Lacer, S.A. | Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung |
ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
BR112013005194A2 (pt) | 2010-09-02 | 2016-05-03 | Gruenenthal Gmbh | forma de dosagem resistente à violação compreendendo sal inorgânico |
WO2012100423A1 (en) * | 2011-01-27 | 2012-08-02 | Eli Lilly And Company | Analgesic compounds, methods, and formulations |
EP2530072A1 (de) | 2011-06-03 | 2012-12-05 | Lacer, S.A. | Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung |
US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
TR201815502T4 (tr) | 2012-04-18 | 2018-11-21 | Gruenenthal Gmbh | Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu. |
US9339484B2 (en) * | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2018517676A (ja) | 2015-04-24 | 2018-07-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時放出および溶媒抽出に対する耐性を有する改変防止製剤 |
EP3346991A1 (de) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Schutz vor oraler überdosierung mit missbrauchssicheren formulierungen mit sofortiger freisetzung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1199764B (de) * | 1963-04-02 | 1965-09-02 | Gruenenthal Chemie | Verfahren zur Herstellung von basisch substituierten Phenolaethern |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
DE19525137C2 (de) * | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
DE19609847A1 (de) * | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
-
1998
- 1998-11-06 ES ES009802329A patent/ES2141688B1/es not_active Expired - Fee Related
-
1999
- 1999-04-11 UA UA2001063799A patent/UA59477C2/uk unknown
- 1999-11-04 DE DE69911235T patent/DE69911235T2/de not_active Expired - Fee Related
- 1999-11-04 DK DK02075837T patent/DK1219623T3/da active
- 1999-11-04 CZ CZ20011500A patent/CZ20011500A3/cs unknown
- 1999-11-04 SI SI9930450T patent/SI1127871T1/xx unknown
- 1999-11-04 CA CA002349245A patent/CA2349245A1/en not_active Abandoned
- 1999-11-04 ES ES02075838T patent/ES2213732T3/es not_active Expired - Lifetime
- 1999-11-04 TR TR2002/00416T patent/TR200200416T2/xx unknown
- 1999-11-04 AU AU10473/00A patent/AU755681B2/en not_active Ceased
- 1999-11-04 EP EP02075837A patent/EP1219623B1/de not_active Expired - Lifetime
- 1999-11-04 AT AT02075838T patent/ATE257817T1/de not_active IP Right Cessation
- 1999-11-04 EP EP99953994A patent/EP1127871B1/de not_active Expired - Lifetime
- 1999-11-04 AP APAP/P/2001/002161A patent/AP1222A/en active
- 1999-11-04 OA OA1200100111A patent/OA11672A/en unknown
- 1999-11-04 US US09/831,177 patent/US6455585B1/en not_active Expired - Fee Related
- 1999-11-04 ID IDW00200101215A patent/ID29017A/id unknown
- 1999-11-04 DK DK02075838T patent/DK1219594T3/da active
- 1999-11-04 AT AT02075837T patent/ATE257837T1/de not_active IP Right Cessation
- 1999-11-04 CN CNB998129259A patent/CN1176902C/zh not_active Expired - Fee Related
- 1999-11-04 EA EA200100476A patent/EA003742B1/ru not_active IP Right Cessation
- 1999-11-04 MX MXPA01004432A patent/MXPA01004432A/es unknown
- 1999-11-04 DE DE69914229T patent/DE69914229T2/de not_active Expired - Fee Related
- 1999-11-04 YU YU29601A patent/YU29601A/sh unknown
- 1999-11-04 SK SK584-2001A patent/SK284068B6/sk unknown
- 1999-11-04 TR TR2001/01160T patent/TR200101160T2/xx unknown
- 1999-11-04 PL PL99347492A patent/PL347492A1/xx unknown
- 1999-11-04 AT AT99953994T patent/ATE249418T1/de not_active IP Right Cessation
- 1999-11-04 TR TR2002/00415T patent/TR200200415T2/xx unknown
- 1999-11-04 WO PCT/ES1999/000352 patent/WO2000027799A1/es not_active Application Discontinuation
- 1999-11-04 EP EP02075838A patent/EP1219594B1/de not_active Expired - Lifetime
- 1999-11-04 GE GEAP19995930A patent/GEP20033116B/en unknown
- 1999-11-04 PT PT02075837T patent/PT1219623E/pt unknown
- 1999-11-04 DK DK99953994T patent/DK1127871T3/da active
- 1999-11-04 SI SI9930540T patent/SI1219594T1/xx unknown
- 1999-11-04 EE EEP200100246A patent/EE200100246A/xx unknown
- 1999-11-04 KR KR10-2001-7005667A patent/KR100453613B1/ko not_active IP Right Cessation
- 1999-11-04 DE DE69914231T patent/DE69914231T2/de not_active Expired - Fee Related
- 1999-11-04 ES ES02075837T patent/ES2213731T3/es not_active Expired - Lifetime
- 1999-11-04 ES ES99953994T patent/ES2207298T3/es not_active Expired - Lifetime
- 1999-11-04 PT PT02075838T patent/PT1219594E/pt unknown
- 1999-11-04 SI SI9930541T patent/SI1219623T1/xx unknown
- 1999-11-04 NZ NZ511739A patent/NZ511739A/xx unknown
- 1999-11-04 IL IL14259299A patent/IL142592A0/xx unknown
- 1999-11-04 HU HU0104218A patent/HUP0104218A3/hu unknown
- 1999-11-04 PT PT99953994T patent/PT1127871E/pt unknown
- 1999-11-04 JP JP2000580979A patent/JP2002529442A/ja active Pending
- 1999-11-04 BR BR9915727-6A patent/BR9915727A/pt not_active IP Right Cessation
-
2001
- 2001-05-03 IS IS5934A patent/IS5934A/is unknown
- 2001-05-04 NO NO20012234A patent/NO20012234L/no unknown
- 2001-05-07 CU CU2001010920010109A patent/CU23006A3/es unknown
- 2001-05-16 CR CR6368A patent/CR6368A/es not_active Application Discontinuation
- 2001-05-17 ZA ZA200104026A patent/ZA200104026B/en unknown
- 2001-05-23 MA MA26211A patent/MA26765A1/fr unknown
- 2001-05-29 HR HR20010412A patent/HRP20010412B1/xx not_active IP Right Cessation
- 2001-06-01 BG BG105556A patent/BG105556A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200104026B (en) | New esters derived from substituted phenyl-cyclohexyl compounds. | |
US20030100598A1 (en) | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | |
HU218481B (hu) | 1-Fenil-3-dimetilamino-propán-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és eljárás e vegyületek előállítására | |
SK17797A3 (en) | 1,4-benzothiazepine-1,1-dioxides, process for producing them and a pharmaceutical composition containing them | |
UA82835C2 (en) | ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon | |
SK161999A3 (en) | 4-phenylpiperidine compounds | |
CZ293971B6 (cs) | Dimethyl-(3-arylbut-3-enyl)aminosloučeniny a způsob jejich výroby | |
WO2002059074A1 (fr) | Analogue de benzylamine | |
US8378143B2 (en) | Methods of making Efavirens and intermediates thereof | |
CZ20022338A3 (cs) | Deriváty aminomethyl-fenyl-cyklohexanu, způsob jejich výroby, léčiva tyto látky obsahující a jejich pouľití | |
KR20070107162A (ko) | 6-디메틸아미노메틸-1-(3-메톡시페닐)-1,3-디하이드록시사이클로헥산 화합물의 인산염 | |
WO2008157657A1 (en) | Deuterium-enriched tenofovir | |
KR840000033B1 (ko) | 이소퀴놀린 유도체의 제조방법 | |
JPH02178279A (ja) | 新規のジベンゾシクロヘプテン誘導体、それらの製造方法及びそれらの薬剤としての使用 | |
JPS6046110B2 (ja) | 1−(4−イソプロピルチオフエニル)−2−n−オクチルアミノプロパノ−ルの製造法 |